• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude+Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Arvinas, Inc. - Common Stock (NQ:ARVN)

9.570 -0.090 (-0.93%)
Streaming Delayed Price Updated: 4:00 PM EDT, May 12, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Arvinas, Inc. - Common Stock

< Previous 1 2 3 4 5 Next >
News headline image
Arvinas Reports First Quarter 2026 Financial Results and Provides Corporate Update
Today 7:05 EDT
From Arvinas Inc.
Via GlobeNewswire
News headline image
Arvinas and Pfizer Enter into a Transaction with Rigel Pharmaceuticals for the Exclusive Global Rights of VEPPANU (vepdegestrant)
Today 7:00 EDT
From Arvinas Inc.
Via GlobeNewswire
News headline image
Arvinas to Report First Quarter 2026 Financial Results on May 12, 2026
May 05, 2026
From Arvinas Inc.
Via GlobeNewswire
News headline image
Arvinas Announces FDA Approval of VEPPANU (vepdegestrant) for the Treatment of ESR1m, ER+/HER2- Advanced Breast Cancer
May 01, 2026
From Arvinas Inc.
Via GlobeNewswire
News headline image
Arvinas Announces Positive Phase 1 Data for ARV-102 Showing Greater Than 50% LRRK2 Degradation in the CSF of Patients with Parkinson’s Disease Treated for 28 Days
March 18, 2026
From Arvinas Inc.
Via GlobeNewswire
News headline image
Arvinas to Present Phase 1 Data for ARV-102, a PROTAC LRRK2 Degrader, in Oral Session at the 2026 International Conference on Alzheimer’s and Parkinson’s Diseases and Related Neurological Disorders
March 11, 2026
From Arvinas Inc.
Via GlobeNewswire
News headline image
Arvinas Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update
February 24, 2026
From Arvinas Inc.
Via GlobeNewswire
News headline image
Arvinas to Participate in Upcoming Investor Conferences
February 23, 2026
From Arvinas Inc.
Via GlobeNewswire
News headline image
Arvinas to Report Fourth Quarter and Full Year 2025 Financial Results on February 24, 2026
February 17, 2026
From Arvinas Inc.
Via GlobeNewswire
News headline image
Arvinas Announces Appointment of Randy Teel, Ph.D., as President, Chief Executive Officer, and Director
February 12, 2026
From Arvinas Inc.
Via GlobeNewswire
News headline image
Arvinas Presents Preclinical Data Supporting Mechanistic Synergies and Enhanced Antitumor Activity with the Combination of ARV-393 and Glofitamab at the 2025 American Society of Hematology Annual Meeting and Exposition
December 06, 2025
From Arvinas Inc.
Via GlobeNewswire
News headline image
Arvinas to Present at Piper Sandler 37th Annual Healthcare Conference
November 26, 2025
From Arvinas Inc.
Via GlobeNewswire
News headline image
Arvinas Announces Data Presentations from the Vepdegestrant (ARV-471) Clinical Development Program at the 2025 San Antonio Breast Cancer Symposium (SABCS)
November 24, 2025
From Arvinas Inc.
Via GlobeNewswire
News headline image
Arvinas Reports Third Quarter 2025 Financial Results and Provides Corporate Update
November 05, 2025
From Arvinas Inc.
Via GlobeNewswire
News headline image
Arvinas to Present Preclinical Data for ARV-393 at the 2025 American Society of Hematology (ASH) Annual Meeting
November 03, 2025
From Arvinas Inc.
Via GlobeNewswire
News headline image
Arvinas to Participate in Upcoming Investor Conferences
November 03, 2025
From Arvinas Inc.
Via GlobeNewswire
News headline image
Arvinas to Report Third Quarter 2025 Financial Results on November 5, 2025
October 29, 2025
From Arvinas Inc.
Via GlobeNewswire
News headline image
Arvinas Presents Preclinical Data for ARV-806 Demonstrating Robust and Differentiated Activity in Models of KRAS G12D-mutated Cancer at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
October 24, 2025
From Arvinas Inc.
Via GlobeNewswire
News headline image
Arvinas to Present Preclinical Data for ARV-806, a PROTAC KRAS G12D Degrader, at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
October 22, 2025
From Arvinas Inc.
Via GlobeNewswire
News headline image
Patient-Reported Outcomes from VERITAC-2 Clinical Trial Support Clinical Benefit of Vepdegestrant in Patients with ESR1-Mutated, ER+/HER2- Advanced or Metastatic Breast Cancer Previously Treated with Endocrine-Based Therapy
October 20, 2025
From Arvinas Inc.
Via GlobeNewswire
News headline image
Arvinas to Present Data from the Vepdegestrant Clinical Development Program at the 2025 European Society for Medical Oncology (ESMO) Congress
October 13, 2025
From Arvinas Inc.
Via GlobeNewswire
News headline image
Arvinas Presents Late Breaking, Positive Phase 1 Clinical Data for ARV-102, a PROTAC LRRK2 Degrader, at the 2025 International Congress of Parkinson’s Disease and Movement Disorders®
October 05, 2025
From Arvinas Inc.
Via GlobeNewswire
News headline image
Arvinas to Present Clinical Data for ARV-102, a PROTAC LRRK2 Degrader, at the 2025 International Congress of Parkinson’s Disease and Movement Disorders®
October 01, 2025
From Arvinas Inc.
Via GlobeNewswire
News headline image
Arvinas Provides Update on Collaboration with Pfizer and Announces Further Actions to Support Value Creation
September 17, 2025
From Arvinas Inc.
Via GlobeNewswire
News headline image
Arvinas to Participate in Upcoming Investor Conferences
August 29, 2025
From Arvinas Inc.
Via GlobeNewswire
News headline image
Arvinas Announces FDA Acceptance of the New Drug Application for Vepdegestrant for the Treatment of ESR1m, ER+/HER2- Advanced Breast Cancer
August 08, 2025
From Arvinas Inc.
Via GlobeNewswire
News headline image
Arvinas Reports Second Quarter 2025 Financial Results and Provides Corporate Update
August 06, 2025
From Arvinas Inc.
Via GlobeNewswire
News headline image
Arvinas to Report Second Quarter 2025 Financial Results on August 6, 2025
July 30, 2025
From Arvinas Inc.
Via GlobeNewswire
News headline image
Arvinas Announces Retirement of Chief Executive Officer and Succession Plan
July 09, 2025
From Arvinas Inc.
Via GlobeNewswire
News headline image
Bragar Eagel & Squire, P.C. Is Investigating Arvinas, Semler, and Abacus and Encourages Investors to Contact the Firm
June 23, 2025
From Bragar Eagel & Squire
Via GlobeNewswire
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap